| 程明月,张 辉,徐 晤,程 伟,燕 军.沙库巴曲缬沙坦联合呋塞米治疗慢性心力衰竭的疗效研究[J].,2019,19(22):4295-4298 |
| 沙库巴曲缬沙坦联合呋塞米治疗慢性心力衰竭的疗效研究 |
| Efficacy of Shakuba Valsartan Combined with Furosemide in the Treatment of Chronic Heart Failure |
| 投稿时间：2019-03-06 修订日期：2019-03-31 |
| DOI：10.13241/j.cnki.pmb.2019.22.020 |
| 中文关键词: 沙库巴曲缬沙坦 呋塞米 慢性心力衰竭 心功能 |
| 英文关键词: Shakuba valsartan Furosemide Chronic heart failure Cardiac function |
| 基金项目:江苏省高校自然科学基金项目（15KJD320003） |
|
| 摘要点击次数: 1080 |
| 全文下载次数: 768 |
| 中文摘要: |
| 摘要 目的：探究沙库巴曲缬沙坦联合呋塞米治疗慢性心力衰竭的临床疗效。方法：选择2017年1月-2018年12月于我院诊治的慢性心力衰竭患者60例，随机将其分为两组。其中，对照组给予呋塞米进行治疗，研究组在对照组基础上联合沙库巴曲缬沙坦进行治疗，对比两组患者的治疗总有效率、治疗前后心功能、血清N端B型脑钠肽(NT-proBNP)、醛固酮(ALD)、细胞间黏附分子-1(ICAM-1)水平的变化及不良反应的发生情况。结果：治疗后，研究组患者的治疗总有效率[96.7%(29/30)]显著高于对照组[80.0%(24/30)](P＜0.05)。两组患者治疗后的左心室射血分数(LVEF)均较治疗前显著升高，左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)均较治疗前明显降低(P＜0.05)，且研究组LVEF显著高于对照组，而LVEDD和LVESD明显低于对照组(P＜0.05)；两组患者治疗后的血清NT-proBNP、ALD、ICAM-1水平均较治疗前显著降低(P＜0.05)，且研究组以上指标均显著低于对照组低(P＜0.05)。对照组患者不良反应发生率[10.0%(3/30)]与研究组[13.3%(4/30)]比较无显著性差异(P＞0.05)。结论：沙库巴曲缬沙坦联合呋塞米治疗慢性心力衰竭的效果显著优于单用呋塞米治疗，其可有效改善患者的心功能且安全性较高，可能与其明显改善患者血清NT-proBNP、ALD、ICAM-1水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical effect of shakuba Valsartan combined with furosemide in the treatment of chronic heart failure. Methods: 60 patients with chronic heart failure who were treated in our hospital from January 2017 to February 2018 were randomly divided into two groups. Among them, the control group was treated with furosemide, and the study group was treated with shakuba valsartan on the basis of the control group. The total effective rate, the changes of cardiac function, serum NT-proBNP, ALD and ICAM-1 levels, and incidence of adverse reactions were compared between the two groups. Results: After treatment, the total effective rate in the study group was [96.7%(29/30)], which was significantly higher than that in the control group [80.0%(24/30)] (P<0.05). The LVEF levels of the twoboth groups were increased after treatment, while the LVEDD and LVESD were decreased (P<0.05), and LVEF was significantly higher in the study group than in the control group, while LVEDD and LVESD were significantly lower in the study group than in the control group (P<0.05). The serum levels of NT-proBNP, ALD and ICAM-1 in the two groups after treatment were significantly lower than those before treatment (P<0.05), and the above indexes in the study group were significantly lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the control group [10.0%(3/30)] and the study group [13.3%(4/30)] (P>0.05). Conclusion: The effect of saponin and fluoxetine combined with furosemide in the treatment of chronic heart failure is significantly better than that of furosemide alone. This method can effectively improve the heart function of patients and have high safety. It may be related to significantly improve the patient's serum NT-proBNP, ALD, ICAM-1 levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
